Compare AU
Compare GNDQ vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are GNDQ and DRUG. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
GNDQ | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 25 | 63 |
Median incremental investment | $2,295.00 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,742.52 | $1,882.65 |
Average age group | > 35 | 26 - 35 |
Key Summary
GNDQ | DRUG | |
|---|---|---|
Strategy | GNDQ.AX was created on 2024-10-11 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The investment objective of the Betashares Wealth Builder Nasdaq 100 Geared (30-40% LVR) Complex ETF is to provide geared exposure to the returns of the Nasdaq-100 Index. There is no assurance or guarantee that the returns of the Fund will meet its investment objective. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | BetaShares Wealthbuilder Nasdaq Geared Complex ETF (100 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | |
Management fee | 0 % | 0.57 % |
Key Summary
GNDQ | DRUG | |
|---|---|---|
Issuer | BetaShares | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 0 % | 0.57 % |
Price | $30.02 | $8.12 |
Size | N/A | $182.401 million |
10Y return | N/A | N/A |
Annual dividend/ distribution yield (5Y) | - % | 1.90 % |
Market | ASX | ASX |
First listed date | 14/10/2024 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
GNDQ | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 25 | 63 |
Median incremental investment | $2,295.00 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,742.52 | $1,882.65 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
GNDQ | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
GNDQ | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |